Document Detail


Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.
MedLine Citation:
PMID:  23151944     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Human γδ T cells display potent cytotoxicity against various tumor cells pretreated with zoledronic acid (Zol). Zol has shown benefits when added to adjuvant endocrine therapy for patients with early-stage breast cancer or to standard chemotherapy for patients with multiple myeloma. Although γδ T cells may contribute to this additive effect, the responsiveness of γδ T cells from early-stage breast cancer patients has not been fully investigated. In this study, we determined the number, frequency, and responsiveness of Vγ2Vδ2 T cells from early- and late-stage breast cancer patients and examined the effect of IL-18 on their ex vivo expansion. The responsiveness of Vγ2Vδ2 T cells from patients with low frequencies of Vγ2Vδ2 T cells was significantly diminished. IL-18, however, enhanced ex vivo proliferative responses of Vγ2Vδ2 T cells and helper NK cells from patients with either low or high frequencies of Vγ2Vδ2 T cells. Treatment of breast cancer patients with Zol alone decreased the number of Vγ2Vδ2 T cells and reduced their ex vivo responsiveness. These results demonstrate that Zol can elicit immunological responses by γδ T cells from early-stage breast cancer patients, but that frequent in vivo treatment reduces Vγ2Vδ2 T cell numbers and their responsiveness to stimulation.
Authors:
Tomoharu Sugie; Kaoru Murata-Hirai; Masashi Iwasaki; Craig T Morita; Wen Li; Haruki Okamura; Nagahiro Minato; Masakazu Toi; Yoshimasa Tanaka
Related Documents :
24530564 - Hypermethylation of mir-203 in endometrial carcinomas.
22538974 - Aurora kinase a outperforms ki67 as a prognostic marker in er-positive breast cancer.
23900794 - Targeting focal adhesion kinase in er+/her2+ breast cancer improves trastuzumab response.
23110034 - Multifocal adenocarcinomas arising within a gastric inverted hyperplastic polyp.
12219324 - Breast-feeding in preterm twins: development of feeding behavior and milk intake during...
2129824 - Carboxyl terminal glycine extended progastrin (gastrin-g) in gastric antral mucosa of p...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-11-15
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  62     ISSN:  1432-0851     ISO Abbreviation:  Cancer Immunol. Immunother.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-12     Completed Date:  2013-06-07     Revised Date:  2014-04-02    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  677-87     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / drug therapy,  immunology*,  pathology,  therapy*
Clinical Trials as Topic
Combined Modality Therapy
Diphosphonates / therapeutic use*
Female
Humans
Imidazoles / therapeutic use*
Immunotherapy, Adoptive / methods
Interleukin-18 / immunology,  therapeutic use*
Killer Cells, Natural / drug effects,  immunology*
Leukocytes, Mononuclear / immunology
Middle Aged
Neoplasm Staging
Receptors, Antigen, T-Cell, gamma-delta / biosynthesis,  immunology*
T-Lymphocytes, Helper-Inducer / drug effects,  immunology*
Grant Support
ID/Acronym/Agency:
AR045504/AR/NIAMS NIH HHS; CA113874/CA/NCI NIH HHS; P50 CA097274/CA/NCI NIH HHS; R01 AR045504/AR/NIAMS NIH HHS; R01 CA113874/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Diphosphonates; 0/Imidazoles; 0/Interleukin-18; 0/Receptors, Antigen, T-Cell, gamma-delta; 118072-93-8/zoledronic acid
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of soluble protein contents from the nematocysts of a model sea anemone sheds light on veno...
Next Document:  Enhancement of the anti-melanoma response of Hu14.18K322A by ?CD40 + CpG.